Oral-B is arguably one of the biggest brands when it comes to electric toothbrushes. However, with so many options available, it can be hard to figure out which model is right for you. Plus, with some ...
Tyler Shipley is an editor for Game Rant who has been writing for the team since 2021. Tyler has a degree in English from the University of Toledo. Some of his favorite games are platformers, but he ...
Orforglipron, a small-molecule, nonpeptide oral GLP-1 receptor agonist, at multiple doses produced significant weight loss and improved cardiometabolic risk factors compared with placebo, according to ...
A GLP-1 drug taken as a daily pill has been shown to produce substantial weight loss in people with obesity but without type 2 diabetes, an international trial has shown. A phase 3 trial of ...
In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial [1] reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, ...
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy.
Cadisegliatin acts in the liver to increase the activity of glucokinase, an enzyme that plays a role in regulating blood glucose levels. A phase 3 clinical trial has begun enrolling patients to assess ...
Eli Lilly announced Phase 3 trials results for its daily, oral GLP-1 drug. Drugmaker Eli Lilly says its oral, daily GLP-1 pill may offer similar weight loss results as weekly GLP-1 shots. Eli Lilly, ...
A daily oral GLP-1 pill can help people with obesity lose about 12% of their body weight, according to early data shared by drugmaker Eli Lilly today. The medication, called orforglipron, may be a ...
With a GLP-1 in pill form for weight loss expected to be FDA-approved by year’s end, obesity medicine physicians said they are gearing up for higher demand and already answering questions about the ...
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results